Simcere Phrama gets China regulator approval to market generic version of Relenza
Simcere Pharmaceutical Group (NYSE: SCR) said its unit Nanjing Simcere Dongyuan Pharmaceutical Co Ltd has received new drug registration approval from the State Food and Drug Administration (SFDA) to manufacture and sell Zanamivir , a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B.
Simcere Pharmaceuitcal Group specializes in the development, manufacturing and marketing of branded generic and proprietary pharmaceuticals in China.
Zanamivir
is marketed globally by GlaxoSmithKline PLC (LSE: GSK) under the trade
name Relenza.
Zanamivir is one of only two WHO approved drugs to
which the new H1N1 strain of influenza A has been shown to be
susceptible. GlaxoSmithKline granted a license to Simcere in 2006 to
manufacture and sell Zanamivir and its formulations in China. Simcere is
the only pharmaceutical company in mainland China that has such a
license.
Related news
- Regency Mines shares up on more positive Mambare results
- Escher Group wins largest contract to date; shares surge
- Chariot Oil & Gas completes 3D seismic survey in Namibia
- Peninsula Energy chairman talks to Proactive Investors in Stocktube Video
- Empire Energy Group hits oil production milestone in Appalachia
- Aminex and Solo Oil to carry out further analysis on Ntorya-1 well
- Angel Biotechnology shares surge as it reveals new contracts worth total of £4.5mln
